Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Study of GBR 1342, a CD38 / CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of single-agent GBR 1342 in subjects with multiple myeloma who have received prior therapies.
Multiple Myeloma
Phase I
Adults
Mol. targeted/Immunotherapy/Biologics
GBR 1342
Cornell, Robert
International
Vanderbilt University
04-05-2018
Treatment
VICCHEMP17111
NCT03309111

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Males or females with multiple myeloma who have exhausted available standard therapies.

Measurable disease, defined as any quantifiable monoclonal protein value

ECOG performance-status score of 2 or less

Life expectancy of at least 3 months

Recovered from any previous surgery and no history of major surgery within the last 28 days prior to start of study drug



Exclusion Criteria:

Any condition that, in the opinion of the Investigator, would interfere with evaluation of the study drug or interpretation of subject safety or study results.

Active infectious disease considered by the Investigator to be incompatible with the protocol.

Evidence of clinically significant cardiovascular and respiratory conditions

Anti-myeloma treatment within 2 weeks

Use of any investigational drug within the past 4 weeks

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: